Company intelligence / Profile preview

OncoMyx Therapeutics

Phoenix, Arizona, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

OncoMyx has generated extensive preclinical data showing that engineered myxoma virus constructs can be delivered intravenously or intratumorally, stimulate anti-tumor immunity, and produce anti-tumor efficacy across a range of solid and hematologic tumor models; the lead multi-armed MYXV candidate is being advanced toward first-in-human clinical trials but has not yet entered the clinic.

Therapeutic areas: OncologyHematology
Modalities: Oncolytic virus therapyBiologic
Industry: Biotech

Drug pipeline

5 assets

myxoma virus

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on OncoMyx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoMyx Therapeutics.

Explore the full profile